LRRK2 and Parkinson disease: Because the kinase activity of LRRK2 is enhanced in PD and reduced upon binding to 14-3-3, stabilizing the interaction between LRRK2 and 14-3-3 using small-molecule compounds is another potential therapeutic strategy for PD.